GDF.ac.2

(redirected from BMP9)

GDF.ac.2

A gene on chromosome 10q11.22 that encodes a member of the bone morphogenetic protein (BMP) family, which regulates cell growth and differentiation in both embryonic and adult tissues. GDF2 it thought to play a role in the adult liver and in differentiation of cholinergic central nervous system neurones.

References in periodicals archive ?

BMP9 and COX-2 form an important regulatory loop in BMP9-induced osteogenic differentiation of mesenchymal stem cells.

Role of Epithelium Sodium Channel in Bone Formation

The list includes NPPS (nucleotide pyrophosphatase)/ENNP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1), (10) TGFB1 (transforming growth factor [beta]1), (23) ESR (estrogen receptor), (24) IL-1[beta], (24) VDR (vitamin D receptor), (25) BMP2, (26) RUNX2, (27) IL-15RA, (28) BMP9, (29) and TGFB3.

2012) Association of a BMP9 haplotype with ossification of the posterior longitudinal ligament (OPLL) in a Chinese population.

Genomic study of ossification of the posterior longitudinal ligament of the spine

Identification and quantification of BMP4, BMP6 and BMP9 in bovine and human serum.

Bone morphogenetic protein levels in osteoarthritis/ Osteoartritte kemik morfogenik protein duzeyleri

BMP9 has also been shown to be involved in a small number of cases.

Hereditary haemorrhagic telangiectasia in North African and sub-Saharan patients

Dalantercept (ACE-041) is an investigational protein therapeutic that inhibits angiogenesis by preventing BMP9 and BMP10, proteins in the TGF- superfamily, from interacting with activin receptor-like kinase 1 (ALK1), a cell-surface receptor found on proliferating vascular endothelial cells.

Acceleron Announces the Initiation of Phase 2 Clinical Trial of Dalantercept (ACE-041) in Patients with Ovarian Cancer

The two poster presentations describe the potential role of activin A as an adverse biomarker for patients with metastatic breast cancer and of BMP9 as a biomarker for the identification and selection of patients with head and neck cancer.

D, from Acceleron, will present data showing elevated expression of bone morphogenetic protein (BMP9) in tumor samples from patients with squamous cell carcinoma of the head and neck (SCCHN), and the potential role for BMP9 as a biomarker for selecting patients who might benefit from treatment with the investigational drug dalantercept - Acceleron's Phase 2 activin receptor-like kinase 1 (ALK1) inhibitor formerly known as ACE-041.

Acceleron and Collaborators Present Data on Potential Biomarkers for Metastatic Breast Cancer and Head and Neck Cancer at the "2012 Markers in Cancer" Conference

ACE-041 is an ALK1 ligand trap that inhibits angiogenesis by preventing BMP9 and BMP10, members of the TGF protein superfamily, from interacting with activin receptor-like kinase 1 (ALK1), a receptor found on proliferating endothelial cells.

Acceleron's ACE-041 Combined with a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma

ACE-041 is a recombinant receptor fusion protein that inhibits angiogenesis by preventing BMP9 and BMP10, proteins in the TGF superfamily, from interacting with activin receptor-like kinase 1 (ALK1), a cell-surface receptor found on proliferating endothelial cells.

Acceleron Presents Positive Results from Phase 1 Study of ACE-041 in Patients with Advanced Cancer

ACE-041 is a recombinant receptor fusion protein that inhibits angiogenesis by preventing BMP9 and BMP10, members of the TGF protein superfamily, from interacting with activin receptor-like kinase 1 (ALK1), a receptor that is found on proliferating endothelial cells.

Acceleron Announces Interim Findings from the ACE-041 Phase 1, First-in-Human Clinical Trial at 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics